Treating inflammation to combat non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic steatohepatitis (NASH) has become the most common chronic liver disease, thereby representing a great burden for patients and healthcare systems. Specific pharmacological therapies for NAFLD are still missing. Inflammation is an important driver in the pathogenesis of NASH, and the mechanisms underlying inflammation in NAFLD represent possible therapeutic targets. In NASH, various intra- and extrahepatic triggers involved in the metabolic injury typically lead to the activation of different immune cells. This includes hepatic Kupffer cells, i.e. liver-resident macrophages, which can adopt an inflammatory phenotype and activate other immune cells by releasing inflammatory cytokines. As inflammation progresses, Kupffer cells are increasingly replaced by monocyte-derived macrophages with a distinct lipid-associated and scar-associated phenotype. Many other immune cells, including neutrophils, T lymphocytes – such as auto-aggressive cytotoxic as well as regulatory T cells – and innate lymphoid cells balance the progression and regression of inflammation and subsequent fibrosis. The detailed understanding of inflammatory cell subsets and their activation pathways prompted preclinical and clinical exploration of potential targets in NAFLD/NASH. These approaches to target inflammation in NASH include inhibition of immune cell recruitment via chemokine receptors (e.g. cenicriviroc), neutralization of CD44 or galectin-3 as well as agonism to nuclear factors like peroxisome proliferator-activated receptors and farnesoid X receptor that interfere with the activation of immune cells. As some of these approaches did not demonstrate convincing efficacy as monotherapies, a rational and personalized combination of therapeutic interventions may be needed for the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Self-citationSingle cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029349 · Cited by 1,146
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
Guilliams, M., Bonnardel, J., Haest, B., Vanderborght, B., Wagner, C., Remmerie, A., Bujko, A., Martens, L., Thoné, T., Browaeys, R., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.018 · Cited by 985
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Self-citationHarrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
Self-citationMouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citationBaeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609
Self-citationRemmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., De Prijck, S., Vanhockerhout, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.004 · Cited by 592
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Pirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564
Wan, J., Benkdane, M., Teixeira-Clerc, F., Bonnafous, S., Louvet, A., Lafdil, F., Pecker, F., Tran, A., Gual, P., Mallat, A., et al. (2014) · Hepatology · doi:10.1002/hep.26607 · Cited by 558
Krenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557
Self-citationAuto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Dudek, M., Pfister, D., Donakonda, S., Filpe, P., Schneider, A., Laschinger, M., Hartmann, D., Hüser, N., Meiser, P., Bayerl, F., et al. (2021) · Nature · doi:10.1038/s41586-021-03233-8 · Cited by 518
Self-citationHepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503
Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9
Garcia-Martinez, I., Santoro, N., Chen, Y., Hoque, R., Ouyang, X., Caprio, S., Shlomchik, M. J., Coffman, R. L., Candia, A., & Mehal, W. Z. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83885 · Cited by 498
Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.027 · Cited by 497
Seidman, J. S., Troutman, T. D., Sakai, M., Gola, A., Spann, N. J., Bennett, H., Bruni, C. M., Ouyang, Z., Li, R. Z., Sun, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.001 · Cited by 443
Gomes, A. L., Teijeiro, A., Burén, S., Tummala, K. S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., & Djouder, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.020 · Cited by 401
Tran, S., Baba, I., Poupel, L., Dussaud, S., Moreau, M., Gélineau, A., Marcelin, G., Magréau-Davy, E., Ouhachi, M., Lesnik, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.003 · Cited by 400
Wang, H., Zhang, H., Wang, Y., Brown, Z. J., Xia, Y., Huang, Z., Shen, C., Hu, Z., Beane, J., Ansa-Addo, E. A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.032 · Cited by 398
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Lee, Y., Doumouras, A. G., Yu, J., Brar, K., Banfield, L., Gmora, S., Anvari, M., & Hong, D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.10.017 · Cited by 371
Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.296 · Cited by 358
Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology · doi:10.1002/hep.31205 · Cited by 347
ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell · doi:10.1016/j.cell.2018.08.020 · Cited by 333
Lefere, S., Puengel, T., Hundertmark, J., Penners, C., Frank, A. K., Guillot, A., de Muynck, K., Heymann, F., Adarbes, V., Defrêne, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.025 · Cited by 310
Self-citationRau, M., Schilling, A.-K., Meertens, J., Hering, I., Weiss, J., Jurowich, C., Kudlich, T., Hermanns, H. M., Bantel, H., Beyersdorf, N., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501175 · Cited by 302
Therapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH
Sutti, S., Jindal, A., Locatelli, I., Vacchiano, M., Gigliotti, L., Bozzola, C., & Albano, E. (2014) · Hepatology · doi:10.1002/hep.26749 · Cited by 270
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
Hirsova, P., Ibrabim, S. H., Gores, G. J., & Malhi, H. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066357 · Cited by 270
NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice
Wree, A., McGeough, M. D., Inzaugarat, M. E., Eguchi, A., Schuster, S., Johnson, C. D., Peña, C. A., Geisler, L. J., Papouchado, B. G., Hoffman, H. M., et al. (2018) · Hepatology · doi:10.1002/hep.29523 · Cited by 266
Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9
Watanabe, A., Hashmi, A., Gomes, D. A., Town, T., Badou, A., Flavell, R. A., & Mehal, W. Z. (2007) · Hepatology · doi:10.1002/hep.21867 · Cited by 262
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.024 · Cited by 260
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis
Ramachandran, P., Matchett, K. P., Dobie, R., Wilson-Kanamori, J. R., & Henderson, N. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0304-x · Cited by 253
Allard, J. P., Aghdassi, E., Mohammed, S., Raman, M., Avand, G., Arendt, B. M., Jalali, P., Kandasamy, T., Prayitno, N., Sherman, M., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.009 · Cited by 247
Bertola, A., Bonnafous, S., Anty, R., Patouraux, S., Saint-Paul, M.-C., Iannelli, A., Gugenheim, J., Barr, J., Mato, J. M., Le Marchand-Brustel, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013577 · Cited by 240
Hou, J., Zhang, J., Cui, P., Zhou, Y., Liu, C., Wu, X., Ji, Y., Wang, S., Cheng, B., Ye, H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135197 · Cited by 239
A subset of Kupffer cells regulates metabolism through the expression of CD36
Blériot, C., Barreby, E., Dunsmore, G., Ballaire, R., Chakarov, S., Ficht, X., De Simone, G., Andreata, F., Fumagalli, V., Guo, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.006 · Cited by 236
Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.003 · Cited by 230
McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446575 · Cited by 225
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222
Hendrikx, T., Porsch, F., Kiss, M. G., Rajcic, D., Papac-Miličević, N., Hoebinger, C., Goederle, L., Hladik, A., Shaw, L. E., Horstmann, H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.004 · Cited by 220
Krenkel, O., Hundertmark, J., Abdallah, A. T., Kohlhepp, M., Puengel, T., Roth, T., Branco, D. P. P., Mossanen, J. C., Luedde, T., Trautwein, C., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318382 · Cited by 220
Self-citationKoda, Y., Teratani, T., Chu, P.-S., Hagihara, Y., Mikami, Y., Harada, Y., Tsujikawa, H., Miyamoto, K., Suzuki, T., Taniki, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24734-0 · Cited by 219
Barrow, F., Khan, S., Fredrickson, G., Wang, H., Dietsche, K., Parthiban, P., Robert, S., Kaiser, T., Winer, S., Herman, A., et al. (2021) · Hepatology · doi:10.1002/hep.31755 · Cited by 210
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209
Self-citationThe Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Cai, J., Zhang, X., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30506 · Cited by 207
Safety profile of autologous macrophage therapy for liver cirrhosis
Moroni, F., Dwyer, B. J., Graham, C., Pass, C., Bailey, L., Ritchie, L., Mitchell, D., Glover, A., Laurie, A., Doig, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0599-8 · Cited by 202
XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis
Deczkowska, A., David, E., Ramadori, P., Pfister, D., Safran, M., Li, B., Giladi, A., Jaitin, D. A., Barboy, O., Cohen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01344-3 · Cited by 197
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193
Li, F., Hao, X., Chen, Y., Bai, L., Gao, X., Lian, Z., Wei, H., Sun, R., & Tian, Z. (2017) · Nature Communications · doi:10.1038/ncomms13839 · Cited by 191
Dendritic Cells Limit Fibroinflammatory Injury in Nonalcoholic Steatohepatitis in Mice
Henning, J. R., Graffeo, C. S., Rehman, A., Fallon, N. C., Zambirinis, C. P., Ochi, A., Barilla, R., Jamal, M., Deutsch, M., Greco, S., et al. (2013) · Hepatology · doi:10.1002/hep.26267 · Cited by 185
Intestinal Microbiota and Nonalcoholic Steatohepatitis
Brandl, K., & Schnabl, B. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000349 · Cited by 169
Rolla, S., Alchera, E., Imarisio, C., Bardina, V., Valente, G., Cappello, P., Mombello, C., Follenzi, A., Novelli, F., & Carini, R. (2016) · Clinical Science · doi:10.1042/cs20150405 · Cited by 158
Han, Y.-H., Shin, K.-O., Kim, J.-Y., Khadka, D. B., Kim, H.-J., Lee, Y.-M., Cho, W.-J., Cha, J.-Y., Lee, B.-J., & Lee, M.-O. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124219 · Cited by 154
Inzaugarat, M. E., Johnson, C. D., Holtmann, T. M., McGeough, M. D., Trautwein, C., Papouchado, B. G., Schwabe, R., Hoffman, H. M., Wree, A., & Feldstein, A. E. (2019) · Hepatology · doi:10.1002/hep.30252 · Cited by 148
Pulli, B., Ali, M., Iwamoto, Y., Zeller, M. W. G., Schob, S., Linnoila, J. J., & Chen, J. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.6108 · Cited by 143
Bruzzì, S., Sutti, S., Giudici, G., Burlone, M. E., Ramavath, N. N., Toscani, A., Bozzola, C., Schneider, P., Morello, E., Parola, M., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.06.015 · Cited by 139
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Rensen, S. S., Bieghs, V., Xanthoulea, S., Arfianti, E., Bakker, J. A., Shiri-Sverdlov, R., Hofker, M. H., Greve, J. W., & Buurman, W. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052411 · Cited by 116
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Self-citationMurine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis
Heier, E.-C., Meier, A., Julich-Haertel, H., Djudjaj, S., Rau, M., Tschernig, T., Geier, A., Boor, P., Lammert, F., & Lukacs-Kornek, V. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.008 · Cited by 94
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Rai, R. P., Liu, Y., Iyer, S. S., Liu, S., Gupta, B., Desai, C., Kumar, P., Smith, T., Singhi, A. D., Nusrat, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.047 · Cited by 86
Kodama, K., Toda, K., Morinaga, S., Yamada, S., & Butte, A. J. (2015) · Diabetes · doi:10.2337/db14-0149 · Cited by 85
Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
Hwang, S., Yun, H., Moon, S., Cho, Y. E., & Gao, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751802 · Cited by 84
Hepatic Stellate Cell-Immune Interactions in NASH
Carter, J. K., & Friedman, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867940 · Cited by 79
Lan, T., Hu, Y., Hu, F., Li, H., Chen, Y., Zhang, J., Yu, Y., Jiang, S., Weng, Q., Tian, S., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.040 · Cited by 75
Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease
Martínez-Chantar, M. L., Delgado, T. C., & Beraza, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640869 · Cited by 67
Macrophages in nonalcoholic fatty liver disease: a role model of pathogenic immunometabolism
Krenkel, O., & Tacke, F. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1604480 · Cited by 66
Self-citationLiu, M., Hu, Y., Yuan, Y., Tian, Z., & Zhang, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00477 · Cited by 65
Miyake, T., Abe, M., Tokumoto, Y., Hirooka, M., Furukawa, S., Kumagi, T., Hamada, M., Kawasaki, K., Tada, F., Ueda, T., et al. (2013) · Hepatology International · doi:10.1007/s12072-012-9345-8 · Cited by 59
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Self-citationInsulin Signaling as a Potential Natural Killer Cell Checkpoint in Fatty Liver Disease
Amer, J., Salhab, A., Noureddin, M., Doron, S., Abu‐Tair, L., Ghantous, R., Mahamid, M., & Safadi, R. (2018) · Hepatology Communications · doi:10.1002/hep4.1146 · Cited by 42
CX3CR1 Mediates the Development of Monocyte-Derived Dendritic Cells during Hepatic Inflammation
Sutti, S., Bruzzì, S., Heymann, F., Liepelt, A., Krenkel, O., Toscani, A., Ramavath, N., Cotella, D., Albano, E., & Tacke, F. (2019) · Cells · doi:10.3390/cells8091099 · Cited by 34
Self-citation
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationThe intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
“These cell death mechanisms involve rapid membrane permeabilization and release of cytoplasmic contents, thereby triggering sterile inflammation 108 .”
BackgroundRecent insights into the pathogenesis and therapeutic targets of chronic liver diseases
Wen, Y., Ma, L., & Ju, C. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100020 · Cited by 31
Shrestha, S., Jeon, J.-H., & Hong, C.-W. (2025) · BMB Reports · doi:10.5483/bmbrep.2024-0058 · Cited by 30
Metadata
- Authors
- Wiering, L., & Tacke, F.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2023-01-01
- Volume
- 256
- Issue
- 1
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W4306796740
- Cited by
- 56
- References
- 96
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.